NDC product
Forfivo XL
NDC 24979-247 · Upsher-Smith Laboratories, LLC
Key facts
| Product NDC | 24979-247 |
|---|---|
| Proprietary name | Forfivo |
| Nonproprietary name | bupropion hydrochloride |
| Substances | BUPROPION HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Upsher-Smith Laboratories, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA022497 |
| Pharmacologic classes | Aminoketone [EPC], Dopamine Uptake Inhibitors [MoA], Increased Dopamine Activity [PE], Increased Norepinephrine Activity [PE], Norepinephrine Uptake Inhibitors [MoA] |
| Marketing start | Dec 15, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: